FDA leader discusses breaking barriers in clinical care Acting FDA commissioner Janet Woodcock explains how government, researchers, doctors and patients can contribute to improving the clinical research system. With more than three decades of experience at the US Food and Drug Administration (FDA), acting commissioner Janet Woodcock has an informed perspective of the government’s contributions to pharmaceutical development, drug safety, and clinical research. She’s seen the agency work closely with the National Institutes of Health, she said, and witnessed “tremendous progress” on encouraging a stronger focus on the clinical trials included in government grants. “ The experience we’ve had working and trying to deal with the coronavirus has shown the power of everybody working together,” she told Outsourcing-Pharma. “